| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Marta Weinstock, Lisandro Luques, Tatyana Poltyrev, Corina Bejar, Shai Shoha. Ladostigil prevents age-related glial activation and spatial memory deficits in rats. Neurobiology of aging. vol 32. issue 6. 2011-09-13. PMID:19625104. |
ladostigil is a new monoamine oxidase (mao) and acetylcholinesterase (ache) inhibitor designed for the treatment of alzheimer's disease. |
2011-09-13 |
2023-08-12 |
rat |
| Yasumasa Yoshiyama, Ayako Kojima, Chieko Ishikawa, Kimihito Ara. Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. Journal of Alzheimer's disease : JAD. vol 22. issue 1. 2011-08-29. PMID:20847440. |
acetylcholinesterase inhibitors (acheis) are widely used to compensate for acetylcholine (ach) depletion in the alzheimer's disease (ad) brain. |
2011-08-29 |
2023-08-12 |
mouse |
| P K Mukherjee, N Satheeshkumar, P Venkatesh, M Venkates. Lead finding for acetyl cholinesterase inhibitors from natural origin: structure activity relationship and scope. Mini reviews in medicinal chemistry. vol 11. issue 3. 2011-08-23. PMID:21222577. |
acetylcholinesterase (ache) inhibitors are considered as promising therapeutic agents for the treatment of several neurological disorders such as alzheimer's disease (ad), senile dementia, ataxia and myasthenia gravis. |
2011-08-23 |
2023-08-12 |
Not clear |
| Dong Hyun Kim, Yearn Seong Choe, Joon Young Choi, Kyung-Han Lee, Byung-Tae Ki. Binding of 2-[18F]fluoro-CP-118,954 to mouse acetylcholinesterase: microPET and ex vivo Cerenkov luminescence imaging studies. Nuclear medicine and biology. vol 38. issue 4. 2011-08-23. PMID:21531291. |
acetylcholinesterase (ache) has been an important cholinergic factor for the diagnosis of alzheimer's disease (ad), because of reduced ache activity in the postmortem brains of ad patients. |
2011-08-23 |
2023-08-12 |
mouse |
| Gwenaëlle Allain-Veyrac, Anne Lebreton, Catherine Collonnier, Pascale Jollie. First case of symmetric drug-related intertriginous and flexural exanthema (sdrife) due to rivastigmine? American journal of clinical dermatology. vol 12. issue 3. 2011-07-20. PMID:21469764. |
rivastigmine is a reversible and noncompetitive acetylcholinesterase inhibitor used for the treatment of alzheimer disease. |
2011-07-20 |
2023-08-12 |
Not clear |
| Fernando Taragan. [Basis of treatment of dementia. Pros and cons of early versus delayed treatment. Rationale]. Vertex (Buenos Aires, Argentina). vol 21 Suppl. 2011-07-19. PMID:21598737. |
the objective of this analysis was to review the clinical benefits of early treatment of alzheimer's disease focusing on data on the use of inhibitors of acetylcholinesterase. |
2011-07-19 |
2023-08-12 |
Not clear |
| P Szymański, A Janik, E Zurek, E Mikiciuk-Olasi. Design, synthesis and biological evaluation of new 2-benzoxazolinone derivatives as potential cholinesterase inhibitors for therapy of alzheimer's disease. Die Pharmazie. vol 66. issue 6. 2011-07-18. PMID:21699076. |
currently acetylcholinesterase inhibitor (achei) therapy is one of the most frequently used methods in the treatment of alzheimer's disease; tacrine, donepezil, rivastygmine and galantamine are applied in different stages of ad. |
2011-07-18 |
2023-08-12 |
Not clear |
| Alfredo Roble. Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately? The open neurology journal. vol 3. 2011-07-14. PMID:19461897. |
between 1993 and 2000 four acetylcholinesterase inhibitors were marketed as a symptomatic treatment for alzheimer's disease (ad), as well as memantine in 2003. |
2011-07-14 |
2023-08-12 |
Not clear |
| Chun-Yan Wang, Wei Zheng, Tao Wang, Jing-Wei Xie, Si-Ling Wang, Bao-Lu Zhao, Wei-Ping Teng, Zhan-You Wan. Huperzine A activates Wnt/β-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 36. issue 5. 2011-07-13. PMID:21289607. |
huperzine a (hupa) is a reversible and selective inhibitor of acetylcholinesterase (ache), and it has multiple targets when used for alzheimer's disease (ad) therapy. |
2011-07-13 |
2023-08-12 |
mouse |
| Robert H Howlan. Alternative drug therapies for dementia. Journal of psychosocial nursing and mental health services. vol 49. issue 5. 2011-07-08. PMID:21553703. |
drugs currently approved by the u.s. food and drug administration (fda) for the treatment of alzheimer's disease include acetylcholinesterase inhibitor (i.e., tacrine, donepezil, rivastigmine, and galantamine) and glutamate-modulating (i.e., memantine) drugs. |
2011-07-08 |
2023-08-12 |
Not clear |
| Florinda Ferreri, Patrizio Pasqualetti, Sara Määttä, David Ponzo, Andrea Guerra, Federica Bressi, Paola Chiovenda, Marco Del Duca, Federica Giambattistelli, Francesca Ursini, Mario Tombini, Fabrizio Vernieri, Paolo Maria Rossin. Motor cortex excitability in Alzheimer's disease: a transcranial magnetic stimulation follow-up study. Neuroscience letters. vol 492. issue 2. 2011-06-21. PMID:21281700. |
transient cognitive and behavioral stabilization of patients with alzheimer's disease (ad) is the main goal of acetylcholinesterase inhibitor (achei) therapy. |
2011-06-21 |
2023-08-12 |
Not clear |
| Marwan Sabbagh, Jeffrey Cumming. Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC neurology. vol 11. 2011-06-14. PMID:21299848. |
symptomatic treatments for moderate to severe alzheimer's disease are approved in the united states and include the acetylcholinesterase inhibitor donepezil and the glutamate receptor antagonist memantine. |
2011-06-14 |
2023-08-12 |
Not clear |
| Marwan Sabbagh, Jeffrey Cumming. Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC neurology. vol 11. 2011-06-14. PMID:21299848. |
herein, we review (1) the scientific data on the importance of cholinergic deficits in alzheimer's disease treatment strategies, (2) the rationale for the use of higher-dose acetylcholinesterase inhibitors in patients with advanced disease, and (3) recent clinical evidence supporting the use of higher-dose donepezil in patients with moderate to severe alzheimer's disease. |
2011-06-14 |
2023-08-12 |
Not clear |
| Kamil Musilek, Marketa Komloova, Ondrej Holas, Martina Hrabinova, Miroslav Pohanka, Vlastimil Dohnal, Florian Nachon, Martin Dolezal, Kamil Kuc. Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage--implications for early Myasthenia gravis treatment. European journal of medicinal chemistry. vol 46. issue 2. 2011-06-08. PMID:21236521. |
inhibitors of acetylcholinesterase are compounds widely used in the treatment of various diseases, such as alzheimer's disease, glaucoma and myasthenia gravis (mg). |
2011-06-08 |
2023-08-12 |
human |
| Mehmet Sofuoglu, Andrew J Waters, James Poling, Kathleen M Carrol. Galantamine improves sustained attention in chronic cocaine users. Experimental and clinical psychopharmacology. vol 19. issue 1. 2011-06-01. PMID:21341919. |
galantamine, a reversible and competitive inhibitor of acetylcholinesterase, is used clinically in the treatment of alzheimer's dementia. |
2011-06-01 |
2023-08-12 |
human |
| Strahil Berkov, Jaume Bastida, Francesc Viladomat, Carles Codin. Development and validation of a GC-MS method for rapid determination of galanthamine in Leucojum aestivum and Narcissus ssp.: a metabolomic approach. Talanta. vol 83. issue 5. 2011-05-31. PMID:21238736. |
galanthamine, an acetylcholinesterase inhibitor marketed as a hydrobromide salt for the treatment of alzheimer's disease, is obtained from some amaryllidaceae plants. |
2011-05-31 |
2023-08-12 |
Not clear |
| Bengt Winblad, Ezio Giacobini, Lutz Frölich, Lawrence T Friedhoff, Gosse Bruinsma, Robert E Becker, Nigel H Grei. Phenserine efficacy in Alzheimer's disease. Journal of Alzheimer's disease : JAD. vol 22. issue 4. 2011-05-25. PMID:20930279. |
to gather preliminary evidence in alzheimer's disease (ad) for the efficacy of phenserine, a non-competitive acetylcholinesterase inhibitor that has independent modulatory effects on amyloid-β generation, a 12-week comparison of patients receiving phenserine (10 and 15 mg bid) or placebo was conducted under double-blind conditions. |
2011-05-25 |
2023-08-12 |
Not clear |
| Shikhar Gupta, Adyary Fallarero, Päivi Järvinen, Daniela Karlsson, Mark S Johnson, Pia M Vuorela, C Gopi Moha. Discovery of dual binding site acetylcholinesterase inhibitors identified by pharmacophore modeling and sequential virtual screening techniques. Bioorganic & medicinal chemistry letters. vol 21. issue 4. 2011-05-23. PMID:21273074. |
dual binding site acetylcholinesterase (ache) inhibitors are promising for the treatment of alzheimer's disease (ad). |
2011-05-23 |
2023-08-12 |
Not clear |
| Robert H Howlan. Drug therapies for cognitive impairment and dementia. Journal of psychosocial nursing and mental health services. vol 48. issue 4. 2011-05-17. PMID:20349884. |
drugs currently approved by the u.s. food and drug administration (fda) for the treatment of alzheimer's disease include acetylcholinesterase inhibitor drugs (tacrine [cognex®], donepezil [aricept®], rivastigmine [exelon®, exelon patch®], and galantamine [reminyl®, razadyne®]) and glutamate-modulating drugs (memantine [namenda®]). |
2011-05-17 |
2023-08-12 |
Not clear |
| I V Damulin, D A Stepkina, A B Lokshin. [Neuromidin in mixed vascular and Alzheimer's dementia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 111. issue 2. 2011-05-05. PMID:21350422. |
the efficacy of neuromidin (ipidacrinum), a nonselective inhibitor of acetylcholinesterase and butyrilcholinesterase was studied in patients with mixed vascular and alzheimer's dementia of mild and moderate severity. |
2011-05-05 |
2023-08-12 |
Not clear |